https://vilalab.org/publications/spontaneous-changes-in-brain-striatal-dopamine-synthesis-and-storage-dynamics-ex-vivo-reveal-end-product-feedback-inhibition-of-tyrosine-hydroxylase/2022-07-08T14:09:26+00:00https://vilalab.org/publications/brain-injections-of-glial-cytoplasmic-inclusions-induce-a-multiple-system-atrophy-like-pathology/2022-07-08T14:10:16+00:00https://vilalab.org/publications/human-%ce%b1-synuclein-overexpression-in-mouse-serotonin-neurons-triggers-a-depressive-like-phenotype-rescue-by-oligonucleotide-therapy/2022-07-08T14:17:51+00:00https://vilalab.org/publications/serum-metabolic-biomarkers-for-synucleinopathy-conversion-in-isolated-rem-sleep-behavior-disorder/2026-08-05T12:28:16+00:00https://vilalab.org/publications/the-spatiotemporal-changes-in-dopamine-neuromelanin-and-iron-characterising-parkinsons-disease/2022-07-08T14:19:46+00:00https://vilalab.org/publications/bioinspired-theranostic-coordination-polymer-nanoparticles-for-intranasal-dopamine-replacement-in-parkinsons-disease/2022-07-08T14:22:18+00:00https://vilalab.org/publications/nurr1-repression-mediates-cardinal-features-of-parkinsons-disease-in-%ce%b1-synuclein-transgenic-mice/2022-07-08T14:23:02+00:00https://vilalab.org/publications/the-cd200r1-microglial-inhibitory-receptor-as-a-therapeutic-target-in-the-mptp-model-of-parkinsons-disease/2022-07-08T08:23:32+00:00https://vilalab.org/publications/guidelines-for-the-use-and-interpretation-of-assays-for-monitoring-autophagy-4th-edition/2026-08-05T11:29:54+00:00https://vilalab.org/publications/mutant-htt-huntingtin-impairs-mitophagy-in-a-cellular-model-of-huntington-disease/2022-07-08T08:27:22+00:00https://vilalab.org/publications/validation-of-a-reversed-phase-uplc-ms-ms-method-to-determine-dopamine-metabolites-and-oxidation-intermediates-in-neuronal-differentiated-sh-sy5y-cells-and-brain-tissue/2022-07-08T08:28:56+00:00https://vilalab.org/publications/cd8-t-cell-nigral-infiltration-precedes-synucleinopathy-in-early-stages-of-parkinsons-disease/2026-08-05T11:28:42+00:00https://vilalab.org/publications/bidirectional-gut-to-brain-and-brain-to-gut-propagation-of-synucleinopathy-in-nonhuman-primates/2022-07-08T08:32:40+00:00https://vilalab.org/publications/identification-of-of-distinc-pathological-signatures-induced-by-patient-derived-alpha-synuclein-structures-in-non-human-primates/2022-07-08T08:34:58+00:00https://vilalab.org/publications/anti-%ce%b1-synuclein-aso-delivered-to-monoamine-neurons-prevents-%ce%b1-synuclein-accumulation-in-a-parkinsons-disease-like-mouse-model-and-in-monkeys/2022-07-08T08:36:40+00:00https://vilalab.org/publications/lrrk2-in-parkinson-disease-challenges-of-clinical-trials/2022-07-08T08:38:34+00:00https://vilalab.org/publications/chitinase-3-like-1-is-neurotoxic-in-primary-cultured-neurons/2022-07-08T08:40:06+00:00https://vilalab.org/publications/sex-dependent-calcium-hyperactivity-due-to-lysosomal-related-dysfunction-in-astrocytes-from-apoe4-versus-apoe3-gene-targeted-replacement-mice/2022-07-08T08:41:46+00:00https://vilalab.org/publications/brain-tyrosinase-overexpression-implicates-age-dependent-neuromelanin-production-in-parkinsons-disease-pathogenesis/2026-08-05T11:35:12+00:00https://vilalab.org/publications/neuromelanin-aging-and-neuronal-vulnerability-in-parkinsons-disease/2026-08-05T11:34:52+00:00https://vilalab.org/publications/intracellular-crowding-by-age-dependent-neuromelanin-accumulation-disrupts-neuronal-proteostasis-and-triggers-parkinson-disease-pathology/2026-08-05T11:34:30+00:00https://vilalab.org/publications/parkinson-disease-substantia-nigra-vulnerability-and-calbindin-expression-enlightening-the-darkness/2022-07-08T08:50:15+00:00https://vilalab.org/publications/the-e3-ubiquitin-ligases-trim17-and-trim41-modulate-%ce%b1-synuclein-expression-by-regulating-zscan21/2022-07-08T08:51:53+00:00https://vilalab.org/publications/defective-mitochondrial-protein-import-contributes-to-complex-i-induced-mitochondrial-dysfunction-and-neurodegeneration-in-parkinsons-disease/2026-08-05T11:32:11+00:00https://vilalab.org/publications/overexpression-of-tfeb-drives-a-pleiotropic-neurotrophic-effect-and-prevents-parkinsons-disease-related-neurodegeneration-2/2026-08-05T11:31:39+00:00https://vilalab.org/publications/lack-of-pathogenic-potential-of-peripheral-%ce%b1-synuclein-aggregates-from-parkinsons-disease-patients/2026-08-05T11:31:17+00:00https://vilalab.org/publications/selective-alpha-synuclein-knockdown-in-monoamine-neurons-by-intranasal-oligonucleotide-delivery-potential-therapy-for-parkinson-disease/2022-07-08T08:58:49+00:00https://vilalab.org/publications/synaptic-regulator-%ce%b1-synuclein-in-dopaminergic-fibers-is-essentially-required-for-the-maintenance-of-subependymal-neural-stem-cells/2022-07-08T09:00:23+00:00https://vilalab.org/publications/the-small-gtpase-rac1-ced-10-is-essential-in-maintaining-dopaminergic-neuron-function-and-survival-against-%ce%b1-synuclein-induced-toxicity/2022-07-08T09:42:25+00:00https://vilalab.org/publications/involvement-of-cellular-prion-protein-in-%ce%b1-synuclein-transport-in-neurons/2022-07-08T09:44:03+00:00https://vilalab.org/publications/mitochondrial-quality-control-in-neurodegenerative-diseases-focus-on-parkinsons-disease-and-huntingtons-disease/2026-08-05T11:33:08+00:00https://vilalab.org/publications/glucocerebrosidase-deficiency-in-dopaminergic-neurons-induces-microglial-activation-without-neurodegeneration/2022-07-08T09:46:39+00:00https://vilalab.org/publications/cerebellar-neurodegeneration-in-a-new-rat-model-of-episodic-hepatic-encephalopathy/2022-07-08T09:48:38+00:00https://vilalab.org/publications/alpha-synuclein-propagation-new-insights-from-animal-models/2022-07-08T09:51:01+00:00https://vilalab.org/publications/the-parkinson-disease-mitochondrial-hypothesis-where-are-we-at/2022-07-08T09:52:29+00:00https://vilalab.org/publications/functional-rescue-of-dopaminergic-neuron-loss-in-parkinsons-disease-mice-after-transplantation-of-hematopoietic-stem-and-progenitor-cells/2022-07-08T09:54:19+00:00https://vilalab.org/publications/guidelines-for-the-use-and-interpretation-of-assays-for-monitoring-autophagy-3rd-edition/2026-08-05T11:30:43+00:00https://vilalab.org/publications/targeting-%ce%b1-synuclein-for-treating-parkinsons-disease-mechanistic-and-therapeutic-considerations/2022-07-08T10:00:50+00:00https://vilalab.org/publications/aberrant-epigenome-in-ipsc-derived-dopaminergic-neurons-from-parkinson-disease-patients/2022-07-08T10:02:41+00:00https://vilalab.org/publications/lewy-body-extracts-from-parkinsons-disease-brains-trigger-%ce%b1-synuclein-pathology-and-neurodegeneration-in-mice-and-monkeys/2026-08-05T11:41:57+00:00https://vilalab.org/publications/bax-channel-activity-mediates-lysosomal-disruption-linked-to-parkinson-disease/2026-08-05T11:41:29+00:00https://vilalab.org/publications/dyrk1a-promotes-dopaminergic-neuron-survival-in-the-developing-brain-and-in-a-mouse-model-of-parkinsons-disease/2022-07-08T10:08:28+00:00https://vilalab.org/publications/optic-atrophy-1-mediates-mitochondria-remodeling-and-dopaminergic-neurodegeneration-linked-to-complex-i-deficiency/2026-08-05T11:40:49+00:00https://vilalab.org/publications/lysosomal-impairment-in-parkinsons-disease/2022-07-08T10:12:22+00:00https://vilalab.org/publications/alpha-synuclein-and-protein-degradation-pathways-in-parkinsons-disease-a-pathological-feed-back-loop/2022-07-08T10:14:58+00:00https://vilalab.org/publications/accumulation-of-mitochondrial-dna-deletions-within-dopaminergic-neurons-triggers-neuroprotective-mechanisms/2026-08-05T11:39:59+00:00https://vilalab.org/publications/mitochondria-and-programmed-cell-death-in-parkinsons-disease-apoptosis-and-beyond/2026-08-05T11:39:38+00:00https://vilalab.org/publications/mitochondrial-biology-and-parkinsons-disease/2026-08-05T11:39:12+00:00https://vilalab.org/publications/guidelines-for-the-use-and-interpretation-of-assays-for-monitoring-autophagy/2026-08-05T11:38:43+00:00https://vilalab.org/publications/lysosomal-dysfunction-in-parkinson-disease-atp13a2-gets-into-the-groove-2/2026-08-05T11:37:40+00:00https://vilalab.org/publications/efficient-generation-of-a9-midbrain-dopaminergic-neurons-by-lentiviral-delivery-of-lmx1a-in-human-embryonic-stem-cells-and-induced-pluripotent-stem-cells/2022-07-08T10:25:31+00:00https://vilalab.org/publications/selective-neuroprotective-effects-of-the-s18y-polymorphic-variant-of-uch-l1-in-the-dopaminergic-system/2022-07-08T11:31:41+00:00https://vilalab.org/publications/disease-specific-phenotypes-in-dopamine-neurons-from-human-ips-based-models-of-genetic-and-sporadic-parkinsons-disease/2022-07-08T11:33:23+00:00https://vilalab.org/publications/loss-of-atp13a2-park9-induces-general-lysosomal-deficiency-implications-for-parkinsons-disease/2022-07-08T11:34:37+00:00https://vilalab.org/publications/oligomeric-%ce%b1-synuclein-is-toxic-in-vivo/2026-08-05T11:36:27+00:00https://vilalab.org/publications/lysosomal-membrane-permeabilization-in-parkinsons-disease/2026-08-05T11:36:06+00:00https://vilalab.org/publications/fighting-neurodegeneration-with-rapamycin-mechanistic-insights/2026-08-05T11:35:37+00:00https://vilalab.org/publications/selective-noradrenergic-vulnerability-in-alpha-synuclein-transgenic-mice/2022-07-08T11:43:13+00:00https://vilalab.org/publications/apoptosis-inducing-factor-deficiency-sensitizes-dopaminergic-neurons-to-parkinsonian-neurotoxins/2026-08-05T11:50:11+00:00https://vilalab.org/publications/pathogenic-lysosomal-depletion-in-parkinsons-disease/2026-08-05T11:49:36+00:00https://vilalab.org/publications/neuronal-nos-and-cyclooxygenase-2-contribute-to-dna-damage-in-a-mouse-model-of-parkinsons-disease/2022-07-08T12:17:00+00:00https://vilalab.org/publications/molecular-pathways-of-programmed-cell-death-in-experimental-parkinsons-disease/2026-08-05T11:49:00+00:00https://vilalab.org/publications/mitochondrial-alterations-in-parkinsons-disease-new-clues/2022-07-08T12:19:30+00:00https://vilalab.org/publications/two-molecular-pathways-initiate-mitochondria-dependent-dopaminergic-neurodegeneration-in-experimental-parkinsons-disease/2026-08-05T11:48:26+00:00https://vilalab.org/publications/complex-i-deficiency-primes-bax-dependent-neuronal-apoptosis-through-mitochondrial-oxidative-damage/2026-08-05T11:47:54+00:00https://vilalab.org/publications/ablation-of-the-inflammatory-enzyme-myeloperoxidase-mitigates-features-of-parkinsons-disease/2022-07-08T13:50:28+00:00https://vilalab.org/publications/mptp-as-a-mitochondrial-neurotoxic-model-of-parkinsons-disease/2022-07-08T13:53:05+00:00https://vilalab.org/publications/interfering-with-programmed-cell-death-in-neurodegenerative-diseases-insights-from-experimental-animal-models-letter-to-editor/2026-08-05T11:47:07+00:00https://vilalab.org/publications/neurodegeneration-what-does-it-mean/2026-08-05T11:45:50+00:00https://vilalab.org/publications/genetic-clues-to-the-pathogenesis-of-parkinsons-disease/2026-08-05T11:45:34+00:00https://vilalab.org/publications/jnk-mediated-induction-of-cox-2-is-required-for-neurodegeneration-in-a-mouse-model-of-parkinsons-disease/2022-07-08T13:59:34+00:00https://vilalab.org/publications/overexpression-of-hahd-ii-abad-rescues-mitochondrial-respiration-and-dopaminergic-neurons-in-the-mptp-model-of-parkinsons-disease/2022-07-08T14:01:26+00:00https://vilalab.org/publications/the-rotenone-model-of-parkinsons-disease/2026-08-05T11:44:46+00:00https://vilalab.org/publications/cox-2-and-neurodegeneration-in-parkinsons-disease/2026-08-05T11:44:27+00:00https://vilalab.org/publications/the-1-methyl-4-phenyl-1236-tetrahydropyridine-mouse-model-a-tool-to-explore-the-pathogenesis-of-parkinsons-disease/2026-08-05T11:43:58+00:00https://vilalab.org/publications/targeting-programmed-cell-death-in-neurodegenerative-diseases/2026-08-05T11:43:29+00:00https://vilalab.org/publications/pathogenic-role-of-glial-cells-in-parkinsons-disease/2026-08-05T11:43:10+00:00https://vilalab.org/publications/apoptosis-as-therapeutic-target/2026-08-05T11:42:50+00:00https://vilalab.org/publications/neurodegeneration-what-is-it-and-where-are-we/2026-08-05T11:56:17+00:00https://vilalab.org/publications/free-radicals-and-nitric-oxide-toxicity-in-parkinsons-disease/2026-08-05T11:55:53+00:00https://vilalab.org/publications/cyclooxygenase-2-is-instrumental-in-parkinson-disease-neurodegeneration/2022-07-08T14:34:49+00:00https://vilalab.org/publications/d-s-hydroxybutyrate-rescues-mitochondrial-respiration-and-mitigates-features-of-parkinsons-disease/2022-07-08T14:36:13+00:00https://vilalab.org/publications/glial-cell-response-a-pathogenic-factor-in-parkinsons-disease/2022-07-08T14:37:27+00:00https://vilalab.org/publications/tyrosine-hydroxylase/2026-08-05T11:55:01+00:00https://vilalab.org/publications/blockade-of-microglial-activation-is-neuroprotective-in-the-1-methyl-4-phenyl-1236-tetrahydropyridine-mouse-model-of-parkinson-disease/2022-07-08T14:41:16+00:00https://vilalab.org/publications/metabolic-changes-in-the-basal-ganglia-of-patients-with-huntingtons-disease-an-in-situ-hybridization-study-of-cytochrome-oxidase-subunit-i-mrna/2022-07-08T14:42:29+00:00https://vilalab.org/publications/increased-expression-and-redistribution-of-the-antiapoptotic-molecule-bcl-xl-in-parkinsonsdisease/2022-07-08T14:43:43+00:00https://vilalab.org/publications/instrumental-activation-of-bid-by-caspase-1-in-a-transgenic-mouse-model-of-als/2022-07-08T14:45:15+00:00https://vilalab.org/publications/resistance-of-%ef%81%a1-synuclein-null-mice-to-the-parkinsonian-neurotoxin-mptp/2026-08-05T11:25:46+00:00https://vilalab.org/publications/mptp-a-review-of-its-mechanisms-of-neurotoxicity/2022-07-08T15:05:26+00:00https://vilalab.org/publications/engineered-modeling-and-the-secrets-of-parkinsons-disease/2026-08-05T11:53:27+00:00https://vilalab.org/publications/the-role-of-glial-cells-in-parkinsons-disease/2026-08-05T11:53:09+00:00https://vilalab.org/publications/the-last-decade-in-parkinsons-disease-research-basic-sciences/2026-08-05T11:52:52+00:00https://vilalab.org/publications/oxidative-post-translational-modifications-of-%ef%81%a1-synuclein-in-the-1-methyl-4-phenyl-1236-tetrahydropyridine-mptp-mouse-model-of-parkinsons-disease/2026-08-05T11:52:38+00:00https://vilalab.org/publications/bax-ablation-prevents-dopaminergic-neurodegeneration-in-the-mptp-mouse-model-of-parkinson-disease/2026-08-05T11:52:13+00:00https://vilalab.org/publications/lack-of-nigral-pathology-in-transgenic-mice-expressing-human-%ef%81%a1-synuclein-driven-by-the-tyrosine-hydroxylase-promoter/2026-08-05T11:51:21+00:00https://vilalab.org/publications/recruitment-of-the-mitochondrial-dependent-apoptotic-pathway-in-amyotrophic-lateral-sclerosis/2022-07-08T15:15:04+00:00https://vilalab.org/publications/ly293558-an-ampa-glutamate-receptor-antagonist-prevents-and-reverses-levodopa-induced-motor-fluctuations-in-parkinsonian-rats/2022-07-08T15:16:38+00:00https://vilalab.org/publications/metabolic-changes-in-the-basal-ganglia-following-nigrostriatal-denervation/2026-08-05T12:04:05+00:00https://vilalab.org/publications/a-new-look-at-the-pathogenesis-of-parkinsons-disease/2022-07-11T10:11:07+00:00https://vilalab.org/publications/the-parkinsonian-toxin-mptp-action-and-mechanism/2026-08-05T12:03:06+00:00https://vilalab.org/publications/%ef%81%a1-synuclein-upregulation-in-substantia-nigra-dopaminergic-neurons-following-the-administration-of-the-parkinsonian-neurotoxin-1-methyl-4-phenyl-1236-tetrahydropyridine-mptp/2026-08-05T11:24:44+00:00https://vilalab.org/publications/time-course-changes-in-metabolic-and-electrophysiologic-neuronal-activity-in-the-subthalamic-nucleus-of-rats-with-unilateral-lesion-of-the-substantia-nigra/2022-07-11T10:19:25+00:00https://vilalab.org/publications/functional-activity-of-zona-incerta-neurons-is-altered-after-nigrostriatal-denervation-in-hemiparkinsonian-rats/2022-07-11T10:20:57+00:00https://vilalab.org/publications/metabolic-activity-of-excitatory-parafascicular-and-pedunculopontine-inputs-to-subthalamic-nucleus-in-a-rat-model-of-parkinsons-disease/2022-07-11T10:22:51+00:00https://vilalab.org/publications/developmental-cell-death-in-dopaminergic-neurons-of-the-substantia-nigra-of-mice/2022-07-11T10:24:38+00:00https://vilalab.org/publications/the-indirect-basal-ganglia-pathway-in-dopamine-d2-receptor-deficient-mice/2026-06-26T11:36:26+00:00https://vilalab.org/publications/systemic-administration-of-nmda-and-ampa-receptor-antagonists-reverses-the-neurochemical-changes-induced-by-nigrostriatal-denervation-in-basal-ganglia/2022-07-11T10:29:16+00:00https://vilalab.org/publications/inducible-nitric-oxide-synthase-stimulates-dopaminergic-neurodegeneration-in-the-mptp-model-of-parkinsons-disease/2026-08-05T12:00:36+00:00https://vilalab.org/publications/re-evaluation-of-the-functional-anatomy-of-the-basal-ganglia-in-normal-and-parkinsonian-states/2026-08-05T12:00:02+00:00https://vilalab.org/publications/consequences-of-nigrostriatal-denervation-on-the-functioning-of-the-basal-ganglia-in-human-and-non-human-primates-an-in-situ-hybridization-study-of-cytochrome-oxidase-subunit-i-mrna/2026-08-05T11:59:15+00:00https://vilalab.org/publications/subthalamotomy-in-parkinsonian-monkeys-behavioural-and-biochemical-analysis/2022-07-11T10:56:36+00:00https://vilalab.org/publications/localization-of-monoamine-oxidases-in-human-peripheral-tissues/2022-07-11T10:58:10+00:00https://vilalab.org/publications/consequences-of-nigrostriatal-denervation-on-the-gabaergic-neurons-of-substantia-nigra-pars-reticulata-and-superior-colliculus-in-parkinsonian-syndromes/2022-07-11T11:07:02+00:00https://vilalab.org/publications/metabolic-activity-of-the-basal-ganglia-in-parkinsonian-syndromes-in-human-and-non-human-primates-a-cytochrome-oxidase-histochemistry-study/2022-07-11T11:08:27+00:00https://vilalab.org/publications/striatal-expression-of-methionine-enkephaline-and-substance-p-rna-messengers-in-parkinsons-disease/2022-07-11T11:10:25+00:00https://vilalab.org/publications/neurotoxic-contribution-of-nadph-oxidase-derived-oxidative-stress-in-the-mptp-model-of-parkinsons-disease/2022-07-11T11:19:32+00:00https://vilalab.org/publications/anti-%ce%b1-synuclein-aso-delivered-to-monoamine-neurons-prevents-%ce%b1-synuclein-accumulation-in-a-parkinsons-disease-like-mouse-model-and-in-monkeys-2/2026-07-16T09:17:07+00:00https://vilalab.org/publications/lysosomal-lipid-alterations-caused-by-glucocerebrosidase-deficiency-promote-lysosomal-dysfunction-chaperone-mediated-autophagy-deficiency-and-alpha-synuclein-pathology/2026-08-05T12:18:40+00:00https://vilalab.org/publications/adult-specific-reelin-expression-alters-striatal-neuronal-organization-implications-for-neuropsychiatric-disorders/2026-07-16T09:23:16+00:00https://vilalab.org/publications/cortical-lewy-body-injections-induce-long-distance-pathogenic-alterations-in-the-non-human-primate-brain/2026-08-05T12:16:50+00:00https://vilalab.org/publications/neuromelanin-accumulation-drives-endogenous-synucleinopathy-in-non-human-primates/2026-08-05T12:16:24+00:00https://vilalab.org/publications/the-role-of-chaperone-mediated-autophagy-in-tissue-homeostasis-and-disease-pathogenesis/2026-08-05T12:15:52+00:00https://vilalab.org/publications/investigating-the-impact-of-physical-activity-on-mitochondrial-function-in-parkinsons-disease-parkex-study-protocol-for-a-randomized-controlled-clinical-trial/2026-08-05T12:15:30+00:00https://vilalab.org/publications/the-consequences-of-gba-deficiency-in-the-autophagy-lysosome-system-in-parkinsons-disease-associated-with-gba-pradas-e-martinez-vicente-m/2026-07-16T09:43:21+00:00https://vilalab.org/publications/sex-differences-in-motor-and-non-motor-symptoms-among-spanish-patients-with-parkinsons-disease/2026-08-05T12:14:27+00:00https://vilalab.org/publications/gene-therapy-with-vmat2-prevents-parkinsons-disease-phenotype-in-humanized-neuromelanin-producing-rats/2026-08-05T12:13:32+00:00https://vilalab.org/publications/relevance-of-%f4%80%86%9fssue%e2%80%90resident-memory-cd8-t-cells-in-the-onset-of-parkinsons-disease-and-examina%f4%80%86%9fon-of-its-possible-e%f4%80%86%9fologies-infec%f4%80%86%9fous-or-autoimmun/2026-08-05T12:10:37+00:00https://vilalab.org/publications/1455/2026-08-05T12:10:06+00:00https://vilalab.org/publications/basic-science-in-movement-disorders-fueling-the-engine-of-translation-into-clinical-practice/2026-07-16T11:04:51+00:00https://vilalab.org/publications/clusterin-deficiency-is-associated-with-a-lack-of-response-to-teriflunomide-in-multiple-sclerosis/2026-08-05T12:09:27+00:00https://vilalab.org/publications/evaluation-of-a-liquid-chromatography-tandem-mass-spectrometry-method-for-the-analysis-of-glucosylceramide-and-galactosylceramide-isoforms-in-cerebrospinal-fluid-of-parkinsons-disease-patients/2026-08-05T12:08:35+00:00https://vilalab.org/publications/csf-d181-sphingolipid-species-in-parkinson-disease-and-dementia-with-lewy-bodies-with-and-without-gba1-variants/2026-08-05T12:07:49+00:00https://vilalab.org/publications/endogenous-interactomes-of-mfn1-and-mfn2-provide-novel-insights-into-interorganelle-communication-and-autophagy/2026-08-05T12:06:58+00:00https://vilalab.org/publications/autophagy-and-protein-quality-control-in-parkinsons-disease/2026-08-05T11:13:00+00:00https://vilalab.org/publications/developing-allosteric-chaperones-for-gba1-associated-disorders-an-integrated-computational-and-experimental-approach/2026-08-05T12:05:38+00:00https://vilalab.org/publications/introducing-pigmo-a-novel-pigmented-mouse-model-of-parkinsons-disease/2026-08-05T10:56:31+00:00https://vilalab.org/publications/neuromelanin-and-selective-neuronal-vulnerability-to-parkinsons-disease/2026-08-05T11:08:17+00:00https://vilalab.org/publications/single-cell-transcriptomics-for-immune-profiling-of-cerebrospinal-fluid-in-neurological-diseases/2026-08-05T11:10:25+00:00https://vilalab.org/publications/neuromelanin-bridging-catecholamine-metabolism-and-neurodegeneration-in-parkinsons-disease/2026-08-05T12:25:00+00:00https://vilalab.org/publications/dysfunctional-lhx6-pallido-subthalamic-projections-mediate-epileptic-events-in-a-mouse-model-of-leigh-syndrome/2026-07-16T13:14:41+00:00https://vilalab.org/publications/phenotypic-characterization-of-an-atp13a2-knockout-rat-model-of-parkinsons-disease/2026-08-05T12:24:12+00:00https://vilalab.org/publications/lrrk2-mutant-microglia-and-neuromelanin-synergize-to-drive-dopaminergic-neurodegeneration-in-an-ipsc-based-parkinsons-disease-mode/2026-08-05T10:59:35+00:00https://vilalab.org/publications/standardised-truai-automated-quantification-of-intracellular-neuromelanin-granules-in-human-brain-tissue-sections/2026-08-05T11:02:25+00:00https://vilalab.org/publications/differential-pathological-dynamics-triggered-by-distinct-parkinson-patient-derived-%ce%b1-synuclein-extracts-in-nonhuman-primates/2026-07-16T13:22:37+00:00https://vilalab.org/publications/longitudinal-neuromelanin-changes-in-prodromal-and-early-parkinsons-disease-in-humans-and-rat-model/2026-08-05T11:03:55+00:00https://vilalab.org/publications/age-dependent-progression-from-clearance-to-vulnerability-in-the-early-response-of-periventricular-microglia-to-%ce%b1-synuclein-toxic-species/2026-08-05T12:22:40+00:00https://vilalab.org/publications/zscan21-mediates-the-pathogenic-transcriptional-induction-of-%ce%b1-synuclein-in-cellular-and-animal-models-of-parkinsons-disease/2026-07-16T13:33:19+00:00https://vilalab.org/publications/autophagy-beyond-earth-dr-ghada-alsaleh-on-aging-cells-and-space/2026-08-05T12:21:50+00:00https://vilalab.org/publications/2-chaperone-mediated-autophagy-sustains-muscle-stem-cell-regenerative-functions-but-declines-with-age/2026-08-05T12:21:12+00:00https://vilalab.org/publications/systematic-assessment-of-matrix-effect-recovery-and-process-efficiency-using-three-complementary-approaches-implications-for-lc-ms-ms-bioanalysis-applied-to-glucosylceramides-in-human-cerebrospinal/2026-08-05T12:20:46+00:00https://vilalab.org/publications/the-human-microglia-atlas-humica-unravels-changes-in-homeostatic-and-disease-associated-microglia-subsets-across-neurodegenerative-conditions/2026-08-05T12:20:05+00:00https://vilalab.org/publications/divergent-tau-pathology-profiles-induced-by-distinct-alpha-synuclein-aggregates-in-non-human-primates/2026-09-23T16:28:09+00:00https://vilalab.org/publications/the-vall-dhebron-initiative-for-parkinson-vhip-cohort-a-prospective-longitudinal-and-observational-study-enrolling-de-novo-parkinsons-disease-patients-for-biomarker-identificati/2026-08-05T11:00:12+00:00https://vilalab.org/publications/effects-of-neuromelanin-buildup-in-rodent-nigral-dopamine-neurons-implications-for-sex-biased-vulnerability-in-parkinsons-disease/2026-08-05T10:54:06+00:00https://vilalab.org/publications/response-to-neuromelanin-t-1-shortening-is-a-necessary-condition/2026-08-05T11:16:53+00:00https://vilalab.org/publications/cell-based-regenerative-interventions-in-parkinsons-disease-overcoming-pharmacological-limitations/2026-08-05T11:20:24+00:00https://vilalab.org/publications/blood-brain-barrier-opening-with-low-intensity-focused-ultrasound-reduces-neuromelanin-accumulation-in-a-non-human-primate-model/2026-09-23T16:27:20+00:00